{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:02:03Z","timestamp":1791511323184,"version":"4.3.4"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,19]]},"DOI":"10.7759\/cureus.97204","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T08:29:44Z","timestamp":1763540984000},"source":"Crossref","is-referenced-by-count":6,"title":["Obesity and Metabolic Syndrome in the 21st Century: A Narrative Review of Cardiometabolic Risk and Global Policy Response"],"prefix":"10.7759","author":[{"given":"Daniel","family":"Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa\u00fal","family":"Marroqu\u00edn Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina N","family":"Angulo Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yareli","family":"Santos Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla","family":"Delgado Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Camacho Esc\u00e1rcega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Herrera Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Antonio","family":"Sanchez Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Alberto","family":"Riancho Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayra E","family":"Rinc\u00f3n Haro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/acref\/9780199976720.001.0001","article-title":"A Dictionary of Epidemiology","author":"Porta M","year":"2014","unstructured":"Porta M. A Dictionary of Epidemiology. Oxford University Press, Oxford; 2014. 10.1093\/acref\/9780199976720.001.0001"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/2048004016633371","article-title":"A clinical perspective of obesity, metabolic syndrome and cardiovascular disease","volume":"5","author":"Han TS","year":"2016","unstructured":"Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis. 2016, 5:2048004016633371. 10.1177\/2048004016633371","journal-title":"JRSM Cardiovasc Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","year":"2025","unstructured":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050. a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025, 405:813-38. 10.1016\/S0140-6736(25)00355-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley TM","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, et al.. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021, 143:e984-1010. 10.1161\/CIR.0000000000000973","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2006.07.005","article-title":"The link between abdominal obesity, metabolic syndrome and cardiovascular disease","volume":"17","author":"Ritchie SA","year":"2007","unstructured":"Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis. 2007, 17:319-26. 10.1016\/j.numecd.2006.07.005","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029617","article-title":"Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management","volume":"137","author":"Neeland IJ","year":"2018","unstructured":"Neeland IJ, Poirier P, Despr\u00e9s JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation. 2018, 137:1391-406. 10.1161\/CIRCULATIONAHA.117.029617","journal-title":"Circulation"},{"key":"ref7","unstructured":"World Obesity Atlas 2025. majority of countries unprepared for rising obesity level. (2025). Accessed: August 22, 2025: https:\/\/www.worldobesity.org\/news\/world-obesity-atlas-2025-majority-of-countries-unprepared-for-rising-obesity-level."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0762-4","article-title":"Association between insulin resistance and the development of cardiovascular disease","volume":"17","author":"Ormazabal V","year":"2018","unstructured":"Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zu\u00f1iga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018, 17:122. 10.1186\/s12933-018-0762-4","journal-title":"Cardiovasc Diabetol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: insights into mechanisms and therapeutic strategy","volume":"7","author":"Li M","year":"2022","unstructured":"Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022, 7:216. 10.1038\/s41392-022-01073-0","journal-title":"Signal Transduct Target Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2010.04.004","article-title":"cJun NH2-terminal kinase 1 (JNK1): roles in metabolic regulation of insulin resistance","volume":"35","author":"Sabio G","year":"2010","unstructured":"Sabio G, Davis RJ. cJun NH2-terminal kinase 1 (JNK1): roles in metabolic regulation of insulin resistance. Trends Biochem Sci. 2010, 35:490-6. 10.1016\/j.tibs.2010.04.004","journal-title":"Trends Biochem Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2019.00028","article-title":"Pathogenesis of insulin resistance and atherogenic dyslipidemia in nonalcoholic fatty liver disease","volume":"7","author":"Akhtar DH","year":"2019","unstructured":"Akhtar DH, Iqbal U, Vazquez-Montesino LM, Dennis BB, Ahmed A. Pathogenesis of insulin resistance and atherogenic dyslipidemia in nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2019, 7:362-70. 10.14218\/JCTH.2019.00028","journal-title":"J Clin Transl Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29024","article-title":"Insulin resistance and atherosclerosis","volume":"116","author":"Semenkovich CF","year":"2006","unstructured":"Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2006, 116:1813-22. 10.1172\/JCI29024","journal-title":"J Clin Invest"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.102.1.42","article-title":"Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)","volume":"102","author":"Festa A","year":"2000","unstructured":"Festa A, D'Agostino R Jr, Howard G, Mykk\u00e4nen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000, 102:42-7. 10.1161\/01.cir.102.1.42","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy SM","year":"2004","unstructured":"Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition. Circulation. 2004, 109:433-8. 10.1161\/01.CIR.0000111245.75752.C6","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New insights into the pathophysiology of dyslipidemia in type 2 diabetes","volume":"239","author":"Taskinen MR","year":"2015","unstructured":"Taskinen MR, Bor\u00e9n J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015, 239:483-95. 10.1016\/j.atherosclerosis.2015.01.039","journal-title":"Atherosclerosis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1042\/bst0311066","article-title":"Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein","volume":"31","author":"Packard CJ","year":"2003","unstructured":"Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans. 2003, 31:1066-9. 10.1042\/bst0311066","journal-title":"Biochem Soc Trans"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.r200004-jlr200","article-title":"Metabolic origins and clinical significance of LDL heterogeneity","volume":"43","author":"Berneis KK","year":"2002","unstructured":"Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002, 43:1363-79. 10.1194\/jlr.r200004-jlr200","journal-title":"J Lipid Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(92)90255-f","article-title":"Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size","volume":"93","author":"Tribble DL","year":"1992","unstructured":"Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 1992, 93:189-99. 10.1016\/0021-9150(92)90255-f","journal-title":"Atherosclerosis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.82.2.495","article-title":"Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk","volume":"82","author":"Austin MA","year":"1990","unstructured":"Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990, 82:495-506. 10.1161\/01.cir.82.2.495","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-008-0010-5","article-title":"Why is HDL functionally deficient in type 2 diabetes?","volume":"8","author":"Kontush A","year":"2008","unstructured":"Kontush A, Chapman MJ. Why is HDL functionally deficient in type 2 diabetes?. Curr Diab Rep. 2008, 8:51-9. 10.1007\/s11892-008-0010-5","journal-title":"Curr Diab Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.95.1.69","article-title":"Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Qu\u00e9bec Cardiovascular Study","volume":"95","author":"Lamarche B","year":"1997","unstructured":"Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despr\u00e9s JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Qu\u00e9bec Cardiovascular Study. Circulation. 1997, 95:69-75. 10.1161\/01.cir.95.1.69","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-10-200311180-00007","article-title":"Use of metabolic markers to identify overweight individuals who are insulin resistant","volume":"139","author":"McLaughlin T","year":"2003","unstructured":"McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003, 139:802-9. 10.7326\/0003-4819-139-10-200311180-00007","journal-title":"Ann Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun M","year":"2010","unstructured":"Jun M, Foote C, Lv J, et al.. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010, 375:1875-84. 10.1016\/S0140-6736(10)60656-3","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine MS","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al.. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017, 376:1713-22. 10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt DL","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, et al.. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019, 380:11-22. 10.1056\/NEJMoa1812792","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark BA","year":"2022","unstructured":"Bergmark BA, Marston NA, Bramson CR, et al.. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation. 2022, 145:1377-86. 10.1161\/CIRCULATIONAHA.122.059266","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil GS","year":"2006","unstructured":"Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006, 444:860-7. 10.1038\/nature05485","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi N","year":"2011","unstructured":"Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011, 11:85-97. 10.1038\/nri2921","journal-title":"Nat Rev Immunol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI57132","article-title":"Inflammatory links between obesity and metabolic disease","volume":"121","author":"Lumeng CN","year":"2011","unstructured":"Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011, 121:2111-7. 10.1172\/JCI57132","journal-title":"J Clin Invest"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker PM","year":"2000","unstructured":"Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000, 342:836-43. 10.1056\/NEJM200003233421202","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.059","article-title":"Obesity, inflammation, and insulin resistance","volume":"132","author":"Shoelson SE","year":"2007","unstructured":"Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007, 132:2169-80. 10.1053\/j.gastro.2007.03.059","journal-title":"Gastroenterology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000131515.03336.f8","article-title":"Role of endothelial dysfunction in atherosclerosis","volume":"109","author":"Davignon J","year":"2004","unstructured":"Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004, 109:III27-32. 10.1161\/01.CIR.0000131515.03336.f8","journal-title":"Circulation"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby P","year":"2009","unstructured":"Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009, 54:2129-38. 10.1016\/j.jacc.2009.09.009","journal-title":"J Am Coll Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker PM","year":"2002","unstructured":"Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002, 347:1557-65. 10.1056\/NEJMoa021993","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwf113","article-title":"Multi-Ethnic Study of Atherosclerosis: objectives and design","volume":"156","author":"Bild DE","year":"2002","unstructured":"Bild DE, Bluemke DA, Burke GL, et al.. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002, 156:871-81. 10.1093\/aje\/kwf113","journal-title":"Am J Epidemiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118709","article-title":"Obesity\/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance","volume":"97","author":"Steinberg HO","year":"1996","unstructured":"Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity\/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996, 97:2601-10. 10.1172\/JCI118709","journal-title":"J Clin Invest"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker PM","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al.. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359:2195-207. 10.1056\/NEJMoa0807646","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker PM","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al.. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017, 377:1119-31. 10.1056\/NEJMoa1707914","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck MA","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018, 20:5-21. 10.1111\/dom.13129","journal-title":"Diabetes Obes Metab"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall JE","year":"2015","unstructured":"Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015, 116:991-1006. 10.1161\/CIRCRESAHA.116.305697","journal-title":"Circ Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12049","article-title":"Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the Obesity Society and the American Society of Hypertension","volume":"15","author":"Landsberg L","year":"2013","unstructured":"Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, Sowers J. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013, 15:14-33. 10.1111\/jch.12049","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.391","article-title":"Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity","volume":"79","author":"Yvan-Charvet L","year":"2011","unstructured":"Yvan-Charvet L, Quignard-Boulang\u00e9 A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int. 2011, 79:162-8. 10.1038\/ki.2010.391","journal-title":"Kidney Int"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2010.02.002","article-title":"Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications","volume":"126","author":"Lambert GW","year":"2010","unstructured":"Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP. Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications. Pharmacol Ther. 2010, 126:159-72. 10.1016\/j.pharmthera.2010.02.002","journal-title":"Pharmacol Ther"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118124","article-title":"Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans","volume":"96","author":"Baron AD","year":"1995","unstructured":"Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest. 1995, 96:786-92. 10.1172\/JCI118124","journal-title":"J Clin Invest"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2012.138","article-title":"Endothelial dysfunction and hypertension in aging","volume":"35","author":"Higashi Y","year":"2012","unstructured":"Higashi Y, Kihara Y, Noma K. Endothelial dysfunction and hypertension in aging. Hypertens Res. 2012, 35:1039-47. 10.1038\/hr.2012.138","journal-title":"Hypertens Res"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.10.2.133","article-title":"Arterial and venous compliance in sustained essential hypertension","volume":"10","author":"Safar ME","year":"1987","unstructured":"Safar ME, London GM. Arterial and venous compliance in sustained essential hypertension. Hypertension. 1987, 10:133-9. 10.1161\/01.hyp.10.2.133","journal-title":"Hypertension"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000242642.42177.49","article-title":"Mechanisms of sympathetic activation in obesity-related hypertension","volume":"48","author":"Esler M","year":"2006","unstructured":"Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension. 2006, 48:787-96. 10.1161\/01.HYP.0000242642.42177.49","journal-title":"Hypertension"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1798-z","article-title":"Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome","volume":"48","author":"Grassi G","year":"2005","unstructured":"Grassi G, Dell'Oro R, Quarti-Trevano F, et al.. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005, 48:1359-65. 10.1007\/s00125-005-1798-z","journal-title":"Diabetologia"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf S","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000, 342:145-53. 10.1056\/NEJM200001203420301","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt B","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999, 341:709-17. 10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial","volume":"376","author":"Esler MD","year":"2010","unstructured":"Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, B\u00f6hm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010, 376:1903-9. 10.1016\/S0140-6736(10)62039-9","journal-title":"Lancet"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29480","article-title":"Obesity and coronary artery disease: an updated systematic review 2022","volume":"14","author":"Manoharan MP","year":"2022","unstructured":"Manoharan MP, Raja R, Jamil A, et al.. Obesity and coronary artery disease: an updated systematic review 2022. Cureus. 2022, 14:e29480. 10.7759\/cureus.29480","journal-title":"Cureus"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.02.025","article-title":"Associations between metabolic syndrome and long-term mortality in patients who underwent percutaneous coronary intervention: an Australian cohort analysis","volume":"219","author":"O'Brien JM","year":"2024","unstructured":"O'Brien JM, Dinh D, Roberts L, et al.. Associations between metabolic syndrome and long-term mortality in patients who underwent percutaneous coronary intervention: an Australian cohort analysis. Am J Cardiol. 2024, 219:25-34. 10.1016\/j.amjcard.2024.02.025","journal-title":"Am J Cardiol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076382","article-title":"The role of oxidative stress enhanced by adiposity in cardiometabolic diseases","volume":"24","author":"\u015awi\u0105tkiewicz I","year":"2023","unstructured":"\u015awi\u0105tkiewicz I, Wr\u00f3blewski M, Nuszkiewicz J, Sutkowy P, Wr\u00f3blewska J, Wo\u017aniak A. The role of oxidative stress enhanced by adiposity in cardiometabolic diseases. Int J Mol Sci. 2023, 24:6382. 10.3390\/ijms24076382","journal-title":"Int J Mol Sci"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-17707-7","article-title":"Association between metabolic syndrome and myocardial infarction among patients with excess body weight: a systematic review and meta-analysis","volume":"24","author":"Sedaghat Z","year":"2024","unstructured":"Sedaghat Z, Khodakarim S, Nejadghaderi SA, Sabour S. Association between metabolic syndrome and myocardial infarction among patients with excess body weight: a systematic review and meta-analysis. BMC Public Health. 2024, 24:444. 10.1186\/s12889-024-17707-7","journal-title":"BMC Public Health"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.704145","article-title":"Impact of metabolic syndrome and it's components on prognosis in patients with cardiovascular diseases: a meta-analysis","volume":"8","author":"Li X","year":"2021","unstructured":"Li X, Zhai Y, Zhao J, et al.. Impact of metabolic syndrome and it's components on prognosis in patients with cardiovascular diseases: a meta-analysis. Front Cardiovasc Med. 2021, 8:704145. 10.3389\/fcvm.2021.704145","journal-title":"Front Cardiovasc Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13127","article-title":"Metabolically healthy overweight\/obesity are associated with increased risk of cardiovascular disease in adults, even in the absence of metabolic risk factors: a systematic review and meta-analysis of prospective cohort studies","volume":"21","author":"Opio J","year":"2020","unstructured":"Opio J, Croker E, Odongo GS, Attia J, Wynne K, McEvoy M. Metabolically healthy overweight\/obesity are associated with increased risk of cardiovascular disease in adults, even in the absence of metabolic risk factors: a systematic review and meta-analysis of prospective cohort studies. Obes Rev. 2020, 21:e13127. 10.1111\/obr.13127","journal-title":"Obes Rev"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18041773","article-title":"Metabolic syndrome and coronary artery disease risk: a meta-analysis of observational studies","volume":"18","author":"Alshammary AF","year":"2021","unstructured":"Alshammary AF, Alharbi KK, Alshehri NJ, Vennu V, Ali Khan I. Metabolic syndrome and coronary artery disease risk: a meta-analysis of observational studies. Int J Environ Res Public Health. 2021, 18:1773. 10.3390\/ijerph18041773","journal-title":"Int J Environ Res Public Health"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1515\/med-2019-0051","article-title":"Suffering from cerebral small vessel disease with and without metabolic syndrome","volume":"14","author":"Mati\u0107 TB","year":"2019","unstructured":"Mati\u0107 TB, Toncev G, Gavrilovi\u0107 A, Aleksi\u0107 D. Suffering from cerebral small vessel disease with and without metabolic syndrome. Open Med (Wars). 2019, 14:479-84. 10.1515\/med-2019-0051","journal-title":"Open Med (Wars)"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-024-01456-x","article-title":"Linking metabolic syndrome, cerebral small vessel disease, and cognitive health: insights from a subclinical population study using TriNetX","volume":"47","author":"Gosalia J","year":"2025","unstructured":"Gosalia J, Spicuzza JM, Bowlus CK, Pawelczyk JA, Proctor DN. Linking metabolic syndrome, cerebral small vessel disease, and cognitive health: insights from a subclinical population study using TriNetX. Geroscience. 2025, 47:3791-806. 10.1007\/s11357-024-01456-x","journal-title":"Geroscience"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2025.149823","article-title":"Impact of obesity on brain structure: a critical review of the evidence from magnetic resonance imaging studies","volume":"1865","author":"Majumder S","year":"2025","unstructured":"Majumder S, Menon K, Borotikar B. Impact of obesity on brain structure: a critical review of the evidence from magnetic resonance imaging studies. Brain Res. 2025, 1865:149823. 10.1016\/j.brainres.2025.149823","journal-title":"Brain Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab135","article-title":"Association between midlife obesity and its metabolic consequences, cerebrovascular disease, and cognitive decline","volume":"106","author":"Morys F","year":"2021","unstructured":"Morys F, Dadar M, Dagher A. Association between midlife obesity and its metabolic consequences, cerebrovascular disease, and cognitive decline. J Clin Endocrinol Metab. 2021, 106:e4260-74. 10.1210\/clinem\/dgab135","journal-title":"J Clin Endocrinol Metab"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009862","article-title":"Metabolic syndrome and risk of stroke: protocol for an update systematic review and meta-analysis","volume":"97","author":"Roever L","year":"2018","unstructured":"Roever L, Resende ES, Diniz AL, et al.. Metabolic syndrome and risk of stroke: protocol for an update systematic review and meta-analysis. Medicine (Baltimore). 2018, 97:e9862. 10.1097\/MD.0000000000009862","journal-title":"Medicine (Baltimore)"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01383-6","article-title":"Association between metabolic syndrome and stroke: a population based cohort study","volume":"23","author":"Moghadam-Ahmadi A","year":"2023","unstructured":"Moghadam-Ahmadi A, Soltani N, Ayoobi F, et al.. Association between metabolic syndrome and stroke: a population based cohort study. BMC Endocr Disord. 2023, 23:131. 10.1186\/s12902-023-01383-6","journal-title":"BMC Endocr Disord"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02282-3","article-title":"Metabolic syndrome parameters' variability and stroke incidence in hypertensive patients: evidence from a functional community cohort","volume":"23","author":"Liu Q","year":"2024","unstructured":"Liu Q, Wu S, Shao J, et al.. Metabolic syndrome parameters' variability and stroke incidence in hypertensive patients: evidence from a functional community cohort. Cardiovasc Diabetol. 2024, 23:203. 10.1186\/s12933-024-02282-3","journal-title":"Cardiovasc Diabetol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13340","article-title":"Obesity, metabolic health and clinical outcomes after incident cardiovascular disease: a nationwide population-based cohort study","volume":"14","author":"Akyea RK","year":"2023","unstructured":"Akyea RK, Ntaios G, Doehner W. Obesity, metabolic health and clinical outcomes after incident cardiovascular disease: a nationwide population-based cohort study. J Cachexia Sarcopenia Muscle. 2023, 14:2653-62. 10.1002\/jcsm.13340","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-022-01475-y","article-title":"Metabolic syndrome and vascular-associated cognitive impairment: a focus on preclinical investigations","volume":"22","author":"Jenkins TA","year":"2022","unstructured":"Jenkins TA. Metabolic syndrome and vascular-associated cognitive impairment: a focus on preclinical investigations. Curr Diab Rep. 2022, 22:333-40. 10.1007\/s11892-022-01475-y","journal-title":"Curr Diab Rep"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.981379","article-title":"Metabolic syndrome and cognition: a systematic review across cognitive domains and a bibliometric analysis","volume":"13","author":"Koutsonida M","year":"2022","unstructured":"Koutsonida M, Markozannes G, Bouras E, Aretouli E, Tsilidis KK. Metabolic syndrome and cognition: a systematic review across cognitive domains and a bibliometric analysis. Front Psychol. 2022, 13:981379. 10.3389\/fpsyg.2022.981379","journal-title":"Front Psychol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah S","year":"2002","unstructured":"Kenchaiah S, Evans JC, Levy D, et al.. Obesity and the risk of heart failure. N Engl J Med. 2002, 347:305-13. 10.1056\/NEJMoa020245","journal-title":"N Engl J Med"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00017.2007","article-title":"Cardiac remodeling in obesity","volume":"88","author":"Abel ED","year":"2008","unstructured":"Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008, 88:389-419. 10.1152\/physrev.00017.2007","journal-title":"Physiol Rev"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.09.040","article-title":"Obesity induces signs of premature cardiac aging in younger patients: the role of mitochondria","volume":"57","author":"Niemann B","year":"2011","unstructured":"Niemann B, Chen Y, Teschner M, Li L, Silber RE, Rohrbach S. Obesity induces signs of premature cardiac aging in younger patients: the role of mitochondria. J Am Coll Cardiol. 2011, 57:577-85. 10.1016\/j.jacc.2010.09.040","journal-title":"J Am Coll Cardiol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.09.041","article-title":"Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus","volume":"105","author":"Aguilar D","year":"2010","unstructured":"Aguilar D, Deswal A, Ramasubbu K, Mann DL, Bozkurt B. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol. 2010, 105:373-7. 10.1016\/j.amjcard.2009.09.041","journal-title":"Am J Cardiol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus WJ","year":"2013","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013, 62:263-71. 10.1016\/j.jacc.2013.02.092","journal-title":"J Am Coll Cardiol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.113.000532","article-title":"Relation of regional fat distribution to left ventricular structure and function","volume":"6","author":"Neeland IJ","year":"2013","unstructured":"Neeland IJ, Gupta S, Ayers CR, et al.. Relation of regional fat distribution to left ventricular structure and function. Circ Cardiovasc Imaging. 2013, 6:800-7. 10.1161\/CIRCIMAGING.113.000532","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022, 387:1089-98. 10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher G","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020, 69:1691-705. 10.1136\/gutjnl-2020-320622","journal-title":"Gut"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1038\/srep33386","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu S","year":"2016","unstructured":"Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016, 6:33386. 10.1038\/srep33386","journal-title":"Sci Rep"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso G","year":"2011","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011, 43:617-49. 10.3109\/07853890.2010.518623","journal-title":"Ann Med"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg H","year":"2010","unstructured":"Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010, 52:1836-46. 10.1002\/hep.24001","journal-title":"Hepatology"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher G","year":"2010","unstructured":"Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010, 363:1341-50. 10.1056\/NEJMra0912063","journal-title":"N Engl J Med"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani A","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018, 41:372-82. 10.2337\/dc17-1902","journal-title":"Diabetes Care"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.030","article-title":"Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease","volume":"62","author":"Petta S","year":"2015","unstructured":"Petta S, Argano C, Colomba D, et al.. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol. 2015, 62:928-33. 10.1016\/j.jhep.2014.11.030","journal-title":"J Hepatol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning JD","year":"2004","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, et al.. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004, 40:1387-95. 10.1002\/hep.20466","journal-title":"Hepatology"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076388","article-title":"Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study","volume":"384","author":"Kim KS","year":"2024","unstructured":"Kim KS, Hong S, Han K, Park CY. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ. 2024, 384:e076388. 10.1136\/bmj-2023-076388","journal-title":"BMJ"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong MJ","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al.. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016, 387:679-90. 10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay MS","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al.. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care. 2018, 41:1801-8. 10.2337\/dc18-0165","journal-title":"Diabetes Care"},{"key":"ref93","article-title":"WHO Discussion Paper on the Development of an Implementation Roadmap 2023-2030 for the WHO Global Action Plan for the Prevention and Control of NCDs 2023-2030","year":"2021","unstructured":"WHO Discussion Paper on the Development of an Implementation Roadmap 2023-2030 for the WHO Global Action Plan for the Prevention and Control of NCDs 2023-2030. World Health Organization, Geneva, Switzerland; 2021."},{"key":"ref94","article-title":"Plan of Action for the Prevention of Obesity in Children and Adolescents","year":"2014","unstructured":"Plan of Action for the Prevention of Obesity in Children and Adolescents. Pan American Health Organization, Washington (DC); 2014."},{"key":"ref95","article-title":"Report of the Commission on Ending Childhood Obesity","year":"2016","unstructured":"Report of the Commission on Ending Childhood Obesity. World Health Organization, Geneva, Switzerland; 2016."},{"key":"ref96","article-title":"Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020","year":"2013","unstructured":"Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020. World Health Organization, Geneva, Switzerland; 2013."},{"key":"ref97","article-title":"Set of Recommendations on the Marketing of Foods and Non-alcoholic Beverages to Children","year":"2010","unstructured":"Set of Recommendations on the Marketing of Foods and Non-alcoholic Beverages to Children. World Health Organization, Geneva, Switzerland; 2010."},{"key":"ref98","article-title":"Fiscal Policies to Promote Healthy Diets: WHO Guideline","year":"2024","unstructured":"Fiscal Policies to Promote Healthy Diets. WHO Guideline. World Health Organization, Geneva, Switzerland; 2024."},{"key":"ref99","article-title":"Fiscal Policies for Diet and Prevention of Noncommunicable Diseases","year":"2011","unstructured":"Fiscal Policies for Diet and Prevention of Noncommunicable Diseases. World Health Organization, Geneva, Switzerland; 2011."},{"key":"ref100","article-title":"Taxes on Sugar-Sweetened Beverages as a Public Health Strategy: The Experience of Mexico","year":"2015","unstructured":"Taxes on Sugar-Sweetened Beverages as a Public Health Strategy. The Experience of Mexico. Pan American Health Organization, Washington (DC); 2015."},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1186\/s12966-022-01262-8","article-title":"Effect of excise tax on sugar-sweetened beverages in Catalonia, Spain, three and a half years after its introduction","volume":"19","author":"Royo-Bordonada M\u00c1","year":"2022","unstructured":"Royo-Bordonada M\u00c1, Fern\u00e1ndez-Escobar C, Gil-Bellosta CJ, Ordaz E. Effect of excise tax on sugar-sweetened beverages in Catalonia, Spain, three and a half years after its introduction. Int J Behav Nutr Phys Act. 2022, 19:24. 10.1186\/s12966-022-01262-8","journal-title":"Int J Behav Nutr Phys Act"},{"key":"ref102","article-title":"Initiative with Draft Decree Whereby the Law of the Special Tax on Production and Services Is Amended and Various Provisions Are Appended","year":"2013","unstructured":"Initiative with Draft Decree Whereby the Law of the Special Tax on Production and Services Is Amended and Various Provisions Are Appended. Senate of the Republic, Congress of the Union, Mexico; 2013."},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2016.1231","article-title":"In Mexico, evidence of sustained consumer response two years after implementing a sugar-sweetened beverage tax","volume":"36","author":"Colchero MA","year":"2017","unstructured":"Colchero MA, Rivera-Dommarco J, Popkin BM, Ng SW. In Mexico, evidence of sustained consumer response two years after implementing a sugar-sweetened beverage tax. Health Aff (Millwood). 2017, 36:564-71. 10.1377\/hlthaff.2016.1231","journal-title":"Health Aff (Millwood)"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.591696","article-title":"Potential impact of the nonessential energy-dense foods tax on the prevalence of overweight and obesity in children: a modeling study","volume":"8","author":"Illescas-Z\u00e1rate D","year":"2020","unstructured":"Illescas-Z\u00e1rate D, Batis C, Ram\u00edrez-Silva I, Torres-\u00c1lvarez R, Rivera JA, Barrientos-Guti\u00e9rrez T. Potential impact of the nonessential energy-dense foods tax on the prevalence of overweight and obesity in children: a modeling study. Front Public Health. 2020, 8:591696. 10.3389\/fpubh.2020.591696","journal-title":"Front Public Health"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002158","article-title":"Projected impact of Mexico's sugar-sweetened beverage tax policy on diabetes and cardiovascular disease: a modeling study","volume":"13","author":"S\u00e1nchez-Romero LM","year":"2016","unstructured":"S\u00e1nchez-Romero LM, Penko J, Coxson PG, et al.. Projected impact of Mexico's sugar-sweetened beverage tax policy on diabetes and cardiovascular disease: a modeling study. PLoS Med. 2016, 13:e1002158. 10.1371\/journal.pmed.1002158","journal-title":"PLoS Med"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12868","article-title":"Impact of sugar-sweetened beverage taxes on purchases and dietary intake: systematic review and meta-analysis","volume":"20","author":"Teng AM","year":"2019","unstructured":"Teng AM, Jones AC, Mizdrak A, Signal L, Gen\u00e7 M, Wilson N. Impact of sugar-sweetened beverage taxes on purchases and dietary intake: systematic review and meta-analysis. Obes Rev. 2019, 20:1187-204. 10.1111\/obr.12868","journal-title":"Obes Rev"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2025.108237","article-title":"Financial incentives for physical activity in adults: systematic review and meta-analysis update","volume":"192","author":"Salmani B","year":"2025","unstructured":"Salmani B, Prapavessis H, Vanderloo LM, Mitchell MS. Financial incentives for physical activity in adults: systematic review and meta-analysis update. Prev Med. 2025, 192:108237. 10.1016\/j.ypmed.2025.108237","journal-title":"Prev Med"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100400","article-title":"A policy study on front-of-pack nutrition labeling in the Americas: emerging developments and outcomes","volume":"18","author":"Crosbie E","year":"2023","unstructured":"Crosbie E, Gomes FS, Olvera J, Rinc\u00f3n-Gallardo Pati\u00f1o S, Hoeper S, Carriedo A. A policy study on front-of-pack nutrition labeling in the Americas: emerging developments and outcomes. Lancet Reg Health Am. 2023, 18:100400. 10.1016\/j.lana.2022.100400","journal-title":"Lancet Reg Health Am"},{"key":"ref109","article-title":"Guiding Principles and Framework Manual for Front-of-Pack Labelling for Promoting Healthy Diet","year":"2019","unstructured":"Guiding Principles and Framework Manual for Front-of-Pack Labelling for Promoting Healthy Diet. World Health Organization, Geneva, Switzerland; 2019."},{"key":"ref110","article-title":"Front of Package Labeling Literature Review","author":"Verrill L","year":"2023","unstructured":"Verrill L, Wu F, Weingaertner D, et al.. Front of Package Labeling Literature Review. US Food and Drug Administration, Silver Spring (MD); 2023."},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.4060\/cc1545en","article-title":"Front-of-Pack Nutrition Labelling in Latin America and the Caribbean - Guidance Note","year":"2023","unstructured":"Front-of-Pack Nutrition Labelling in Latin America and the Caribbean - Guidance Note. FAO, PAHO, UNICEF, Santiago, Chile; 2023. 10.4060\/cc1545en"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2020.06.035","article-title":"Effect of front-of-package nutrition labeling on food purchases: a systematic review","volume":"191","author":"An R","year":"2021","unstructured":"An R, Shi Y, Shen J, et al.. Effect of front-of-package nutrition labeling on food purchases: a systematic review. Public Health. 2021, 191:59-67. 10.1016\/j.puhe.2020.06.035","journal-title":"Public Health"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1186\/s12966-021-01148-1","article-title":"Estimated effects of the implementation of the Mexican warning labels regulation on the use of health and nutrition claims on packaged foods","volume":"18","author":"Cruz-Casarrubias C","year":"2021","unstructured":"Cruz-Casarrubias C, Tolentino-Mayo L, Vandevijvere S, Barquera S. Estimated effects of the implementation of the Mexican warning labels regulation on the use of health and nutrition claims on packaged foods. Int J Behav Nutr Phys Act. 2021, 18:76. 10.1186\/s12966-021-01148-1","journal-title":"Int J Behav Nutr Phys Act"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2023.106587","article-title":"Impact of front-of-pack nutrition labelling in consumer understanding and use across socio-economic status: a systematic review","volume":"187","author":"Shrestha A","year":"2023","unstructured":"Shrestha A, Cullerton K, White KM, Mays J, Sendall M. Impact of front-of-pack nutrition labelling in consumer understanding and use across socio-economic status: a systematic review. Appetite. 2023, 187:106587. 10.1016\/j.appet.2023.106587","journal-title":"Appetite"},{"key":"ref115","unstructured":"MODIFICACI\u00d3N a la Norma Oficial Mexicana NOM-051-SCFI\/SSA1-2010, Especificaciones generales de etiquetado para alimentos y bebidas no alcoh\u00f3licas preenvasados-Informaci\u00f3n comercial y sanitaria, publicada el 5 de abril de 2010. (2020). Accessed. September 2, 2025: https:\/\/www.dof.gob.mx\/normasOficiales\/8150\/seeco11_C\/seeco11_C.html."},{"key":"ref116","article-title":"Quantitative Research on Front of Package Labeling on Packaged Foods","year":"2024","unstructured":"Quantitative Research on Front of Package Labeling on Packaged Foods. US Food and Drug Administration, Silver Spring (MD); 2024."},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthplace.2011.08.021","article-title":"Built environment, physical activity, and obesity: what have we learned from reviewing the literature?","volume":"18","author":"Ding D","year":"2012","unstructured":"Ding D, Gebel K. Built environment, physical activity, and obesity: what have we learned from reviewing the literature?. Health Place. 2012, 18:100-5. 10.1016\/j.healthplace.2011.08.021","journal-title":"Health Place"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthplace.2012.06.003","article-title":"Green space and physical activity: an observational study using Health Survey for England data","volume":"18","author":"Mytton OT","year":"2012","unstructured":"Mytton OT, Townsend N, Rutter H, Foster C. Green space and physical activity: an observational study using Health Survey for England data. Health Place. 2012, 18:1034-41. 10.1016\/j.healthplace.2012.06.003","journal-title":"Health Place"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1177\/0017896906069378","article-title":"A systematic review of the relationship between socio-economic position and physical activity","volume":"65","author":"Gidlow C","year":"2006","unstructured":"Gidlow C, Johnston LH, Crone D, Ellis N, James D. A systematic review of the relationship between socio-economic position and physical activity. Health Educ J. 2006, 65:338-67. 10.1177\/0017896906069378","journal-title":"Health Educ J"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1456","article-title":"Association between active commuting and incident cardiovascular disease, cancer, and mortality: prospective cohort study","volume":"357","author":"Celis-Morales CA","year":"2017","unstructured":"Celis-Morales CA, Lyall DM, Welsh P, et al.. Association between active commuting and incident cardiovascular disease, cancer, and mortality: prospective cohort study. BMJ. 2017, 357:j1456. 10.1136\/bmj.j1456","journal-title":"BMJ"},{"key":"ref121","article-title":"Benefits of Urban Parks: A Systematic Review","author":"Konijnendijk CC","year":"2013","unstructured":"Konijnendijk CC, Annerstedt M, Nielsen AB, Maruthaveeran S. Benefits of Urban Parks: A Systematic Review. International Federation of Parks and Recreation Administration (IFPRA), Copenhagen & Alnarp; 2013."},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046271","article-title":"Association between built environment and physical activity in Latin American countries: a multicentre cross-sectional study","volume":"11","author":"Barreno M","year":"2021","unstructured":"Barreno M, Sisa I, Y\u00e9pez Garc\u00eda MC, et al.. Association between built environment and physical activity in Latin American countries: a multicentre cross-sectional study. BMJ Open. 2021, 11:e046271. 10.1136\/bmjopen-2020-046271","journal-title":"BMJ Open"},{"key":"ref123","article-title":"Global Action Plan on Physical Activity 2018-2030: More Active People for a Healthier World","year":"2018","unstructured":"Global Action Plan on Physical Activity 2018-2030. More Active People for a Healthier World. World Health Organization, Geneva, Switzerland; 2018."},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246419","article-title":"An economic analysis of the health-related benefits associated with bicycle infrastructure investment in three Canadian cities","volume":"16","author":"Whitehurst DG","year":"2021","unstructured":"Whitehurst DG, DeVries DN, Fuller D, Winters M. An economic analysis of the health-related benefits associated with bicycle infrastructure investment in three Canadian cities. PLoS One. 2021, 16:e0246419. 10.1371\/journal.pone.0246419","journal-title":"PLoS One"},{"key":"ref125","article-title":"WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care","year":"2020","unstructured":"WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care. World Health Organization, Geneva, Switzerland; 2020."},{"key":"ref126","article-title":"La Nueva Agenda Urbana","year":"2016","unstructured":"La Nueva Agenda Urbana. United Nations, Quito, Ecuador; 2016."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/421498-obesity-and-metabolic-syndrome-in-the-21st-century-a-narrative-review-of-cardiometabolic-risk-and-global-policy-response","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T08:29:49Z","timestamp":1763540989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/421498-obesity-and-metabolic-syndrome-in-the-21st-century-a-narrative-review-of-cardiometabolic-risk-and-global-policy-response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":126,"URL":"https:\/\/doi.org\/10.7759\/cureus.97204","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}